Analyst Price Target is $77.50
▲ +82,346.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SQZ Biotechnologies in the last 3 months. The average price target is $77.50, with a high forecast of $150.00 and a low forecast of $20.00. The average price target represents a 82,346.81% upside from the last price of $0.09.
Current Consensus is
Hold
The current consensus among 4 contributing investment analysts is to hold stock in SQZ Biotechnologies. This Hold consensus rating has held steady for over two years.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Read More